The federal contract IDV awarded by the Department of Veterans Affairs (VA) to Jubilant Draximage Radiopharmacies, Inc. (doing business as Jubilant Radiopharma), a self-certified small disadvantaged business, is for the supply of radiopharmaceuticals. The $740,177.94 firm-fixed-price delivery order contract is part of a larger $39.8 million multiple-award Indefinite Delivery Contract (IDC) with the VA's Network Contracting Office 8, as well as additional IDVs with the VA and Defense Health Agency (DHA) worth up to $6.6 million. These contracts enable the VA and DHA to efficiently procure critical nuclear medicine products, such as Ga-68 Dotatate, iodine I-123, and technetium-99m, which are used in diagnostic imaging and cancer treatment procedures for veterans and military personnel across the United States.
The original solicitation was a pre-solicitation notice for an Indefinite Delivery/Indefinite Quantity (IDIQ) contract for radiopharmaceuticals to be supplied to the Jesse Brown VA Medical Center in Chicago, Illinois. The three-year contract period, from February 1, 2025, to January 31, 2028, provides a stable procurement framework for the VA facility to secure its pharmaceutical supply needs. While the pre-solicitation notice did not specify potential award values, budget ranges, or anticipated quantities, it indicated that the contract would be open to all qualified vendors, with no set-aside designations.
Generated 2/20/25, 9:04 AM